Parkinson’s disease is one of the most common neurodegenerative diseases and characterised by necrosis of dopaminergic neurons and a resulting impairment of the motor system. Parkinson’s patients present symptoms such as tremor, bradykinesia and rigour, in later disease stages also depression and anxiety. Over the course of the disease, many Parkinson’s patients develop dementia.

A pathological feature of Parkinson’s disease is synucleinopathy, i.e. the intracellular aggregation of alpha-synuclein in form of so-called Lewy bodies. Further synucleinopathies are dementia with Lewy bodies (DLB) and multisystem atrophy (MSA).

Diagnosis of Parkinson’s disease is mainly based on anamnesis and clinical analysis of patients. However, an early and clear differential diagnosis can be difficult even for specialists. Therefore, biomarkers are urgently required, which can be used as diagnostic and prognostic markers.

Alpha-synuclein in CSF is today the most promising potential marker of Parkinson’s disease. The majority of published studies show lowered alpha-synuclein values in CSF of patients with synucleinopathy compared to healthy individuals.

  • Hochspezifischer ELISA zur Bestimmung von Alpha-Synuclein im Liquor
  • Optimiertes Protokoll: Ergebnisse in 4:00 Stunden
  • Effiziente Abarbeitung: Einheitliche Protokolle der Neurodegenerations-ELISA
  • Komfortable Automatisierungslösungen
ProductSample typeRegulatory statusOrder no.
Alpha-synuclein ELISACSFRUO*EQ 6545-9601-L

*For Research use only